Furthermore (as recently reported for MCL1 in the case of triple-negative breast cancer [34]), predictive signatures should additionally take into account not only mRNA expression, but also protein levels of MARCH5 and BCL2 family members. This evidence concerns the gene MCL1 and triple-negative breast carcinoma.